That's fair enough, but it doesn't necessarily mean it's covered legally for the future, and that's why we have this bill. So it may be helpful in terms of that one therapeutic product, but we don't know whether it will apply to other ones. I think we have to look at it systematically, and not just in terms of one product.
This is actually a very important amendment. A number of witnesses, I think, pointed out that the bill had a shortcoming around what the definition was.